Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name ABL1 T315I
Gene Variant Detail

ABL1 T315I (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04329325 Phase II Dasatinib + Dexamethasone + Methotrexate Blinatumomab + Dasatinib + Methotrexate Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Active, not recruiting USA 0
NCT05384587 Phase II Asciminib Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE) Active, not recruiting USA 0
NCT04925479 Phase Ib/II Asciminib Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia Recruiting USA | TUR | POL | NLD | ITA | HUN | GRC | FRA | DEU 5
NCT03874858 Phase II Nilotinib Asciminib + Nilotinib De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination (DANTE) Active, not recruiting ITA 0
NCT06236724 Phase II Asciminib Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Recruiting USA 0
NCT03459534 Phase III Radotinib A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs Recruiting TUR 3
NCT02311998 Phase Ib/II Bosutinib + Inotuzumab ozogamicin Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML Completed USA 0
NCT01593254 Phase II Imatinib Dasatinib Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN) Completed USA | POL | ITA | HUN | FRA | ESP | CZE | CAN | BRA | BEL | AUT | ARG 3
NCT02782403 Phase Ib/II Axitinib + Bosutinib Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia Terminated USA 0
NCT04835584 Phase Ib/II Dasatinib + KRT-232 KRT-232 + Nilotinib KRT-232 and TKI Study in Chronic Myeloid Leukemia Recruiting USA | POL | ITA | FRA | ESP | CAN 2
NCT03106779 Phase III Bosutinib Asciminib Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs Active, not recruiting USA | TUR | ROU | NLD | LBN | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | AUS | ARG 6
NCT02228382 FDA approved Bosutinib Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Terminated USA | SWE | NOR | ITA | FRA | ESP | DEU | AUT 0
NCT01744665 Phase II Nilotinib Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5. (ENESTgoal) Completed USA 0
NCT02081378 Phase I Asciminib Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL Completed USA | NLD | ITA | FRA | ESP | DEU | AUS 3
NCT03595917 Phase I Asciminib + Blinatumomab + Dasatinib + Prednisone ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML Recruiting USA 0
NCT06423911 Phase III Bosutinib + Olverembatinib Olverembatinib Study of Olverembatinib (HQP1351) in Patients With CP-CML (POLARIS-2) Recruiting USA 0
NCT04160546 Phase II Aspirin + Ponatinib Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) (ResToP) Active, not recruiting ESP 0
NCT02629692 Phase Ib/II K0706 Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to >=3 Prior CML Therapies Active, not recruiting USA | TUR | ROU | ITA | HUN | GBR | FRA | ESP | BEL 2
NCT04793399 Phase Ib/II Atezolizumab + Bosutinib Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients Terminated ESP 0
NCT06163430 Phase I TERN-701 CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia Not yet recruiting USA 0
NCT02538926 Phase II Imatinib Rituximab Cyclophosphamide Prednisone Doxorubicin + Etoposide + Vincristine Sulfate Asparaginase Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Withdrawn USA 0